David Graham is set to tell FDA advisers today to pull diabetes pill Avandia from the U.S. market, according to Bloomberg.
Avandia, made by Britain-based GlaxoSmithKline, racked up $2 billion in U.S. sales last year but has been losing market share since May, when a medical journal reported that it raised the risk of heart attacks in patients taking it.
Sales of Avandia fell 22 percent in the second quarter while sales of a Lilly diabetes pill, Byetta, rose 54 percent, to $152 million. Lilly co-markets Byetta with San Diego-based Amylin Pharmaceuticals.
Lilly also receives royalties from Actos, another competitor to Avandia, which it used to market it the United States for Japan-based Takeda Pharmaceutical Co.